About: Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on December 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2013 (ast) наукова стаття, опублікована в грудні 2013 (uk) مقالة علمية نشرت في ديسمبر 2013 (ar) scientific article published on December 2013 (en)
publication date	wds:Q37353441-F05B388D-9E32-42C5-B5E2-A44145D330B6
publication date	2013-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37353441-4DB468BA-F8B0-4BDC-A4E5-BEBA7542FCF1
language of work or name	English
cites work	wds:Q37353441-17D2D924-2D3D-48C6-8B66-39E5D7ECC06F wds:Q37353441-1BF38580-866F-417E-95E9-D2613CC20F29 wds:Q37353441-1F645AFA-FC47-4F0C-9EE4-AEF6E4B430B6 wds:Q37353441-22588356-14B9-46AB-8D1F-A014E87F7C40 wds:Q37353441-327950F0-D407-4D27-AD5C-1CB4BD3E7D5F wds:Q37353441-36A612F8-D027-4249-89D1-83F242CB6800 wds:Q37353441-3A9CA4EE-C3B4-4D87-8DC4-6D7189333F2A wds:Q37353441-41C8C732-F3A8-4866-8A80-8EA4EB0BB895 wds:Q37353441-41DD899C-60B4-45F1-842A-0D9FBFC50C94 wds:Q37353441-4F07EDBE-FD05-490B-AA57-E542212924FB wds:Q37353441-6547B2C3-FEE1-43DC-95CC-ABFAA95E749E wds:Q37353441-7FCA879C-C94B-4E22-A1D6-EA6CBC93C359 wds:Q37353441-830239E7-F57C-45A7-BB4E-CD110657154B wds:Q37353441-90B20283-A1FE-437B-AD18-2CF1A9553DE8 wds:Q37353441-9126AA4D-19C4-4A1C-89F9-E2B1948AA5A8 wds:Q37353441-9ACBB85B-0246-41BA-8E22-509E92E793E0 wds:Q37353441-A9E94166-6672-4CCD-84AF-37D4CE5D5681 wds:Q37353441-AC4E0589-A2F6-4152-920C-AC7A6C7AC115 wds:Q37353441-BA777E70-DD9E-4550-9F27-CF2D20331197 wds:Q37353441-BE8886C5-2DD4-4111-883F-FF6913375F4F wds:Q37353441-C188EE88-A31D-4804-816E-0A8B67BE9C19 wds:Q37353441-CE05E9F5-4E19-4E4E-BD08-9531FCD5EF0D wds:Q37353441-D6EDB347-11E1-4FCE-8EFF-1B20B1FA79FC wds:Q37353441-DBF0D961-EDAB-47C2-B6B9-E4D1C68869E2 wds:Q37353441-DDE37ABF-790E-4B3E-B28E-1F2D718CC4AB wds:Q37353441-DE38956F-9145-458E-8BA0-950A0EBE7C63 wds:Q37353441-E00E5415-394D-4070-A385-ACBAB2609EC9 wds:Q37353441-E22184EB-64CF-4CC5-9270-1BED7ADA4855 wds:Q37353441-E7C066B5-F2BE-4969-A713-5E64E43CEC7D wds:Q37353441-E9862D92-3E7D-438C-A598-9FBCB50A1913 wds:Q37353441-EFCDEF53-3B37-43EB-8C49-B2602B99EB19 wds:Q37353441-FBBFCF6A-55EA-4B4D-BB76-28487554F879 wds:Q37353441-FF435C58-3B5C-4B4F-8DEA-F39AB4C39BFA
cites work	The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Atrial fibrillation and obesity--results of a meta-analysis The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers Anticoagulating obese patients in the modern era. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study Apixaban versus warfarin in patients with atrial fibrillation Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Apixaban or enoxaparin for thromboprophylaxis after knee replacement Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Apixaban versus enoxaparin for thromboprophylaxis after hip replacement Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies Mechanism-based concepts of size and maturity in pharmacokinetics Obesity and the risk of heart failure Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Apixaban in patients with atrial fibrillation Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings Apixaban metabolism and pharmacokinetics after oral administration to humans Overweight, obesity, and the risk of recurrent venous thromboembolism Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...] Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Patient-specific factors predictive of warfarin dosage requirements Relationships between body mass indices and surgical replacements of knee and hip joints Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects Development of a dosing strategy for enoxaparin in obese patients Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance Dosing of unfractionated heparin in obese patients with venous thromboembolism Error in body weight estimation leads to inadequate parenteral anticoagulation.
author name string	wds:Q37353441-0036C358-9AD4-485F-AE56-DB432AEE48CB wds:Q37353441-45F45BE4-C334-4F60-8994-BB786093FBD0 wds:Q37353441-870074C9-F277-4E10-A27B-7594E2A63B97 wds:Q37353441-89AFFC8A-1B0E-4150-8FFB-2A188A53A8AA wds:Q37353441-AEB2D5F6-A269-4A34-895F-BB482C40F17E wds:Q37353441-CFD421A3-6C57-4E6E-B689-94E82FE9BF93 wds:Q37353441-E0179B74-387E-42FA-A2A0-9EBC24ACE367 wds:Q37353441-E81E1F51-D10E-4000-B077-4290366A56BB
author name string	Vijay V Upreti Frank P LaCreta Wonkyung Byon Jessie Wang Janice Pursley

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software